Advances in Cancer Immunotherapy: Enhancing the Immune Response and Addressing Therapeutic Challenges
DOI:
https://doi.org/10.61173/vzsn1s98Keywords:
Cancer, immunotherapy, challengesAbstract
Cancer is the top cause of death around the world. In 2022, nearly 20 million people were diagnosed with cancer, and about 9.7 million died from it. In China, almost 5 million new cancer cases were reported, with over 2.5 million fatalities. Immunotherapy is a new way to treat cancer. It boosts the body’s immune system to fight cancer cells. This method is less harmful to patients and more precise than older treatments like chemotherapy and radiation. There are different kinds of immunotherapy, including vaccines, treatments with substances that boost the immune system, transferring cells, and blocking proteins that stop the immune system from working. Even though immunotherapy is helpful, it can have side effects and tumors can become resistant to it. Each person’s tumor is unique, which makes treatment tricky. Sometimes, tumors can change and resist the therapy. We also don’t have enough markers to tailor treatments to each person’s needs. This review discusses the response of immune system, and how immunotherapy can be used to treat cancer.
References
[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
[2] Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW, He J. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221-231.
[3] Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160-177.
[4] How does a cancer vaccine work? Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00588-9
[5] Murillo R, Ordóñez-Reyes C. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Int J Gynecol Cancer. 2019;29(8):1317-1326.
[6] Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237-253.
[7] Diab A, Tannir NM, Bentebibel SE, et al. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov. 2020;10(8):1158-1173.
[8] Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(62):62-68.
[9] Guerder S, Flavell RA. T-cell activation. Curr Biol. 1995;5(8):866-8.
[10] Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22.
[11] Walsh DA, Lake DS, Snedden EW, et al. Demonstration of sub-luminal propagation of single-cycle terahertz pulses for particle acceleration. Nat Commun. 2017;8(1):421.
[12] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-32.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
